SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Howlander M, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review 1975-2008. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1973_2008/. [Accessed April 5, 2012.]
  • 2
    Parkin DM, Shin HR, Bray F, et al. Estimating of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer. 2008; 127: 2893-2917.
  • 3
    Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics 2011. CA Cancer J Clin. 2011; 61: 212-236.
  • 4
    Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-Small Cell Lung Cancer Collaborative Group. BMJ. 1995; 311: 899-909.
  • 5
    Schiller JH, Harrington D, Belani CP, et al. Comparison of 4 chemotherapy regimens for advanced NSCLC. N Engl J Med. 2002; 346: 92-98.
  • 6
    Smith EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of 2 cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group EORTC 08975. J Clin Oncol. 2003; 21: 3909-3917.
  • 7
    Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-2550.
  • 8
    Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22: 1589-1597.
  • 9
    Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26: 3543-3551.
  • 10
    Johnson D, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004; 11: 2184-2191.
  • 11
    Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010; 21: 1804-1809.
  • 12
    Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009; 374: 1432-1440.
  • 13
    Patel JD, Hensing TA, Rademaker A, et al. Phase II trial pemetrexed and carboplatin plus bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009; 27: 3284-3289.
  • 14
    Genentech Inc. Avastin product information. Available at: http://www.gene.com/gene/products/information/oncology/avastin/. [Accessed April 5, 2012.]
  • 15
    Spigel DR, Hainsworth JD, Shipley DL, et al. A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer. J Thorac Oncol. 2012; 7: 196-202.
  • 16
    Eli Lilly and Company. A study of pemetrexed, carboplatin and bevacizumab in patients with nonsquamous non-small cell lung cancer. National Clinical Trial NCT00762034. Available at: http://clinicaltrials.gov/ct2/show/NCT00762034. [Accessed April 5, 2012.]
  • 17
    Hoffmann-La Roche. AVAPERL1 study: a study of Avastin (bevacizumab) with or without pemetrexed as maintenance therapy after Avastin in first line in patients with non-squamous non-small cell lung cancer. National Clinical Trial NCT00961415. Available at: http://clinicaltrials.gov/ct2/show/NCT00961415. [Accessed April 5, 2012.]
  • 18
    Barlesi F, de Castro J, Dvornichenko V, et al. AVAPERL (MO22089): final efficacy outcomes for patients with advanced non-squamous non-small cell lung cancer (nsNSCLC) randomised to continuation maintenance (mtc) with bevacizumab (bev) or bev+pemetrexed (pem) after first-line (1L) bev-cisplatin (cis)-pem treatment (Tx). Paper presented at: 2011 European Multidisciplinary Cancer Congress; September 23–27, 2011; Stockholm, Sweden. Abstract 34LBA.
  • 19
    Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007; 99: 847-857.
  • 20
    Eastern Cooperative Oncology Group, National Cancer Institute. Bevacizumab or pemetrexed disodium alone or in combination after induction therapy in treating patients with advanced non-squamous non-small cell lung cancer. National Clinical Trial NCT01107626. Available at: http://clinicaltrials.gov/ct2/show/NCT01107626. [Accessed April 5, 2012.]